GlassScriptPhysician profile
Engracio Cortes
NPI 1902820996
$2,627.86
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $173 · 2021: $2,140 · 2022: $203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,813.95 | 2019-2021 | |
| Kite Pharma, INC. | $176.25 | 2020-2022 | |
| Incyte Corporation | $113.79 | 2020-2021 | |
| Pfizer INC. | $93.66 | 2021 | |
| Celgene Corporation | $89.54 | 2022 | |
| Global Blood Therapeutics, INC. | $71.44 | 2020-2021 | |
| Amgen INC. | $60.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $54.69 | 2019 | |
| Tactile Systems Technology INC | $32.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.00 | 2022 | |
| Exelixis INC. | $17.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.72 | 2020 | |
| Eisai INC. | $17.71 | 2019 | |
| Kyowa Kirin, INC. | $15.63 | 2019 | |
| Sobi, INC | $13.77 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $11.66 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Engracio Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.